| Nonalcoholic Steatohepatitis
Rezdiffra vs Wegovy
Side-by-side clinical, coverage, and cost comparison for nonalcoholic steatohepatitis.Deep comparison between: Rezdiffra vs Wegovy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWegovy has a higher rate of injection site reactions vs Rezdiffra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wegovy but not Rezdiffra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rezdiffra
Wegovy
At A Glance
Oral
Once daily
THR-beta agonist
SC injection
Once weekly
GLP-1 receptor agonist
Indications
- Nonalcoholic Steatohepatitis
- Obesity
- Nonalcoholic Steatohepatitis
Dosing
Nonalcoholic Steatohepatitis >=100 kg: 100 mg orally once daily; administer with or without food; swallow tablets whole.
Obesity Adults: maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg; pediatric patients aged 12 years and older: 2.4 mg (or 1.7 mg) SC injection once weekly.
Nonalcoholic Steatohepatitis 2.4 mg SC injection once weekly (maintenance) after escalation from 0.25 mg; may reduce to 1.7 mg once weekly if 2.4 mg not tolerated.
Cardiovascular risk reduction Maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg.
Contraindications
—
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or to any excipient in WEGOVY injection or WEGOVY tablet
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, dizziness
Serious Hepatotoxicity, cholelithiasis, acute cholecystitis, obstructive pancreatitis (gallstone)
Most common (>=2%) Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, hair loss, dysesthesia
Serious Risk of thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, heart rate increase, pulmonary aspiration during anesthesia
Postmarketing Acute pancreatitis and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, rash, urticaria, pulmonary aspiration, acute kidney injury
Pharmacology
Resmetirom is a partial agonist of thyroid hormone receptor-beta (THR-beta) that selectively stimulates THR-beta in the liver to reduce intrahepatic triglycerides, while actions outside the liver (heart, bone) are largely mediated through THR-alpha, which resmetirom activates to a lesser degree.
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor, regulating appetite and caloric intake, stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and delaying gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rezdiffra
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Wegovy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Rezdiffra
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (5/8)
Wegovy
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Rezdiffra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Wegovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Rezdiffra Copay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$349/momo
Wegovy Self-Pay Program - InjectableCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RezdiffraView full Rezdiffra profile
WegovyView full Wegovy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.